Nektar Therapeutics Q3 2024 Earnings Preview
Nektar Therapeutics (NASDAQ:NKTR) is scheduled to announce Q3 earnings results on Thursday, November 7th, after market close. The consensus EPS Estimate is -$0.21 (-10.5% Y/Y) and the consensus Revenue Estimate is $18.
Nektar: Q3 Earnings Snapshot
SAN FRANCISCO — SAN FRANCISCO — Nektar Therapeutics (NKTR) on Thursday reported a loss of $37.1 million in its third quarter. On a per-share basis, the San Francisco-based company said it had a loss of 18 cents. The results beat Wall Street expectations.
Block: Q3 Earnings Snapshot
The average estimate of eight analysts surveyed by Zacks Investment Research was also for earnings of 88 cents per share. The mobile payments services provider posted revenue of $5.98 billion in the period,
Qurate Retail: Q3 Earnings Snapshot
Qurate Retail Group, Inc. (QRTEA) on Thursday reported a loss of $23 million in its third quarter. On a per-share basis, the Englewood, Colorado-based company said it had a loss of 6 cents. The online commerce holding company posted revenue of $2.
Chatham Lodging: Q3 Earnings Snapshot
Chatham Lodging Trust (CLDT) on Thursday reported a key measure of profitability in its third quarter. The results met Wall Street expectations. The West Palm Beach, Florida-based real estate investment trust said it had funds from operations of $17.
DraftKings: Q3 Earnings Snapshot
DraftKings Inc. (DKNG) on Thursday reported a loss
FiercePharma10h
Biologics CDMO Avid Bioservices to go private with $1.1B sale to Ampersand, GHO Capital
Just days after laying out $90 million to acquire Nektar Therapeutics’ Alabama manufacturing plant, Ampersand Capital ...
Zacks.com on MSN47m
Nektar Therapeutics (NKTR) Reports Q3 Loss, Tops Revenue Estimates
Nektar (NKTR) delivered earnings and revenue surprises of 21.74% and 55.24%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Nektar presents late-breaking results from Phase 2 Study of NKTR-255
Therapeutics and collaborators at The University of Texas MD Anderson Cancer Center presented late-breaking results from a Phase ...
FiercePharma3d
Nektar pads wallet with $90M manufacturing plant sale to Ampersand
After a protracted rough patch—which has included layoffs, partnership terminations and lawsuits—San Francisco’s Nektar ...
GlobalData on MSN2d
Nektar Therapeutics to sell Alabama facility to Ampersand
The transaction includes $70m in cash and a $20m retained equity position for Nektar in a new Ampersand portfolio company.
Eczema Drug Developer Nektar Gains Analyst Confidence With 400% Upside Potential
Piper Sandler has initiated coverage on Nektar Therapeutics Inc (NASDAQ:NKTR), citing the company’s lead asset ...
bovnews2d
Piper Sandler Issues Overweight Rating for Nektar Therapeutics (NKTR) Stock
On Monday, Nektar Therapeutics (NKTR) stock saw a modest uptick, ending the day at $1.33 which represents a slight increase of $0.10 or 8.13% from the prior close of $1.23. The stock opened at $1.37 ...
Nektar Therapeutics to Participate in Upcoming Investor Conferences
Nektar Therapeutics (Nasdaq: NKTR) today announced that the company will be webcasting its participation in the upcoming conferences: ...
Nektar To Sell Manufacturing Facility In Alabama, Reagent Supply Business To Ampersand
(RTTNews) - Nektar Therapeutics (NKTR), Monday announced a decision to sell its Alabama-based commercial-scale manufacturing facility and PEGylation reagent supply business to Ampersand Capital ...
MM&M12h
Rx Rundown: Avid Biosciences, Novo Nordisk, Zealand Pharma and more
Nektar Therapeutics is selling its Huntsville, Alabama, manufacturing plant and reagent supply business to private equity firm Ampersand Capital Partners for $90 million. Ascendis Pharma and Novo ...
BioPharma Dive1d
Moderna said to shuffle sales leadership; Vertex records first Casgevy sale
Stephen Hoge will now oversee vaccine sales at Moderna, per a Bloomberg report. Elsewhere, Intra-Cellular unveiled an ...